KYMR

Kymera Therapeutics, Inc.
CAPPED RATING

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics, Inc. (KYMR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (A+); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.7 / 5.0
C+
Value
C
Factor Score 2.3 / 5.0
Growth
F
Factor Score 0.6 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
B+
Factor Score 3.5 / 5.0
Revisions
A+
Factor Score 5.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -24.8
EV / EBITDA -25.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 8.3%
Price Return 12M 100.7%
Catalyst Signal 0.00
Market Cap $10.9B
TTM Revenue $102.2M
Price / Sales 106.2
ROE -27.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 C (2.3) F (0.6) C- (1.9) B+ (3.5) A+ (5.0) C+ (2.7)
2026-11-06 C (2.4) F (0.6) C- (1.9) B+ (3.8) A+ (5.0) C+ (2.7)
2026-10-30 C (2.4) C- (2.1) C (2.3) B+ (3.8) A+ (5.0) B- (3.1)
2026-10-23 C (2.5) C- (2.1) C (2.3) B (3.3) A+ (5.0) B- (3.0)
2026-10-16 C (2.5) C- (2.0) C (2.3) B (3.2) A+ (5.0) B- (3.0)
Page 1 of 8
…